Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex...

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Metformin, a common hypoglycemic drug, demonstrates anti-tumor properties.
• Its precise mechanism in inhibiting tumor growth, particularly in cervical cancer, is under investigation.
• Previous research linked metformin to the inhibition of long non-coding RNA MALAT1/miR-142-3p in cervical cancer cells.

Purpose of the Study:

• To investigate metformin's role in modulating the anti-tumor immune response in cervical cancer.
• To explore the impact of metformin on natural killer (NK) cell cytotoxicity in the context of cervical cancer.
• To elucidate the molecular pathways involved in metformin's immunomodulatory effects.

Main Methods:

• Cell viability, apoptosis, and cell cycle assays were performed using cell counting kit-8 and flow cytometry.
• NK cell cytotoxicity was assessed via lactate dehydrogenase (LDH) release assays.
• Protein and gene expression levels were quantified using immunoblotting and quantitative real-time PCR, respectively. In vivo efficacy was evaluated using tumor xenograft models.

Main Results:

• Metformin suppressed cervical cancer cell proliferation and xenograft growth, inhibiting markers like PCNA, p-PI3K, and p-Akt.
• The drug induced apoptosis and cell cycle arrest in cervical cancer cells, while upregulating DDR-1 and p53.
• Metformin enhanced NK cell cytotoxicity by modulating MICA and HSP70 expression on cancer cells via the PI3K/Akt pathway.

Conclusions:

• Metformin demonstrates immunopotentiating capabilities against cervical cancer.
• The drug enhances NK cell-mediated anti-tumor immunity through the PI3K/Akt pathway.
• Metformin presents a promising candidate for combination therapy in cervical cancer treatment, potentially alongside immunotherapy.